Ypsomed to move production to Germany, increase output in US, Bloomberg News reports
Published by Global Banking & Finance Review®
Posted on August 5, 2025
1 min readLast updated: January 22, 2026

Published by Global Banking & Finance Review®
Posted on August 5, 2025
1 min readLast updated: January 22, 2026

Ypsomed is shifting production to Germany and increasing U.S. output due to potential 39% tariffs on Swiss imports, as reported by Bloomberg.
(Reuters) -Swiss medical technology company Ypsomed is planning to move some production to Germany and increase its output in the U.S. due to the threat of 39% tariffs on imports from Switzerland, Bloomberg News reported on Tuesday, citing its CEO Simon Michel.
(Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Sahal Muhammed)
Ypsomed is relocating some production to Germany due to the threat of 39% tariffs on imports from Switzerland.
The company plans to increase its output in the U.S. as part of its strategy to adapt to the tariff situation.
The information about Ypsomed's production changes was reported by Bloomberg News.
Explore more articles in the Finance category
